|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008286,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0152035,
umls-concept:C0332281,
umls-concept:C0871261,
umls-concept:C1333253,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1882417,
umls-concept:C2911692
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-2-7
|
|
pubmed:abstractText |
Previous studies have demonstrated that the -141C Ins/Del and TaqI A polymorphisms in the DRD2 gene affect the density of the dopamine D2 receptor. The present study examines the correlation between these two polymorphisms and the therapeutic response to chlorpromazine, a typical antipsychotic drug, in 135 inpatients with schizophrenia. Clinical symptoms were evaluated using the Brief Psychiatry Rating Scale (BPRS) before and after 8 weeks of treatment with 300-600 mg/day of chlorpromazine. Our results show that genotyping -141C Ins/Del may help to predict the efficacy of chlorpromazine treatment (P=0.01) due to the fact that patients with no Del allele showed greater improvement than those with Del allele on the overall BPRS (P=0.03), and that, therefore, the potential for therapy in patients with schizophrenia is related to the -141C Ins/Del polymorphism in the DRD2 gene. However, no such relationship was found for the TaqI A polymorphism.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Chlorpromazine,
http://linkedlifedata.com/resource/pubmed/chemical/DRD4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine D2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine D4,
http://linkedlifedata.com/resource/pubmed/chemical/Taq Polymerase
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0304-3940
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
7
|
|
pubmed:volume |
376
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1-4
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15694263-Adult,
pubmed-meshheading:15694263-Antipsychotic Agents,
pubmed-meshheading:15694263-China,
pubmed-meshheading:15694263-Chlorpromazine,
pubmed-meshheading:15694263-Female,
pubmed-meshheading:15694263-Gene Deletion,
pubmed-meshheading:15694263-Genetic Predisposition to Disease,
pubmed-meshheading:15694263-Genotype,
pubmed-meshheading:15694263-Humans,
pubmed-meshheading:15694263-Male,
pubmed-meshheading:15694263-Polymorphism, Genetic,
pubmed-meshheading:15694263-Psychiatric Status Rating Scales,
pubmed-meshheading:15694263-RNA, Messenger,
pubmed-meshheading:15694263-Receptors, Dopamine D2,
pubmed-meshheading:15694263-Receptors, Dopamine D4,
pubmed-meshheading:15694263-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:15694263-Schizophrenia,
pubmed-meshheading:15694263-Taq Polymerase
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.
|
|
pubmed:affiliation |
Bio-X Life Science Research Center, Shanghai Jiao Tong University, 1954 Huashan Road, Shanghai 200030, PR China.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
